Characteristics of hospitalized patients with confirmed COVID-19 and their hospital management

Abstract

Objective: To determine the risk factors of mortality among hospitalized COVID-19 patients.

Methods: This retrospective study used hospitalization records collected by the Indonesia Health Social Security Administrator Agency (Badan Penyelenggara Jaminan Sosial Kesehatan-BPJS Kesehatan). A total of 38277 eligible patients with confirmed COVID-19 were analyzed. The dependent variable of the study was the discharge status (death or recovery) of COVID-19. Independent variables were history of morbidity and disease-related occurrence, type of room health facilities, length of stay and demographic variables (sex, age). The analyses use bivariate and multivariate logistic regression to determine the dominating variable associated with all these variables.

Results: Of the 38 277 inpatients with PCR-confirmed COVID-19, 31051 (81.1%) were discharged and 7226 (18.9%) died. Risk of death was positively associated with older age (aOR 5.74, 95% CI 4.20-7.87 for 19-64 years old; aOR 13.75, 95% CI 9.99-18.92 for 65 years above), male sex (aOR 1.13, 95% CI 1.07-1.19), treated in ICU without ventilator (aOR 5.84, 95% CI 5.41-6.30) and had comorbid respiratory diseases (aOR 5.39, 95% CI 4.93-5.90), but negatively associated with hospital stay of 15 days or longer (aOR 0.39, 95% CI 0.36-0.43).

Conclusions: COVID-19 related death during hospitalization was associated with duration and type of treatment, and existing medical condition among the inpatient individuals during COVID-19 pandemic in DKI Jakarta. The findings of the study suggest importance of appropriate and timely medical intervention and care.

Keywords

Inpatients / COVID-19 / Death / Risk of factors / Indonesia

References

[1] World Health Organization. WHO coronavirus disease (COVID-19) dashboard with vaccination data, 2022. [Online]. Available from: https://covid19.who.int/%0Ahttps://covid19.who.int/%0Ahttps://covid19.who.int/region/searo/country/bd. [Accessed on 17 May 2023].

[2] World Health Organization. Tracking SARS-CoV-2 variants, 2021. [Online]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants. [Accessed on 22 May 2023].

[3] Alexandar S, Ravisankar M, Kumar R, Jakkan K. A comprehensive review on COVID-19 delta variant. Int J Pharmacol Clin Res 2021; 5(2): 83-85. doi: 10.1101/2021.06.20.21259195v1.full-text.

[4] Smith VG. Episode #45-delta variant. [Online]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5/episode-45delta-variant. [Accessed on 22 May 2023].

[5] Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Pearson CAB, et al. COVID-19 length of hospital stay: A systematic review and data synthesis. BMC Med 2020; doi: 10.1186/s12916-020-01726-3.

[6] Siddique SM, Tipton K, Leas B, Greysen SR, Mull NK, Lane-Fall M, et al. Interventions to reduce hospital length of stay in high-risk populations: A systematic review. JAMA Netw Open 2021; 4(9): 1-13. doi: 10.1001/jamanetworkopen.2021.25846.

[7] World Health Organization. COVID-19 weekly epidemiological update. [Online]. Available from: https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update. [Accessed on 20 May 2023].

[8] World Health Organization. Clinical management of COVID-19. 2021. [Online]. Available from: https://iris.who.int/bitstream/handle/10665/349321/WHO-2019-nCoV-clinical-2021.2-eng.pdf?sequence=1. [Accessed on 20 May 2023].

[9] Kementerian Kesehatan Republik Indonesia. Pedoman pencegahan dan pengendalian coronavirus disease (COVID-19), Juli 2020. DKI Jakarta: Kementerian Kesehatan RI; 2020.

[10] World Health Organization. International statistical classification of diseases and related health problems. 10th ed. Geneva, Switzerland: WHO Press; 2010.

[11] World Health Organization. International statistical classifisical of diseases and related helath problems. 5th ed. Geneva, Switzerland: WHO Press; 2016.

[12] Rapid Research Forum (RRIF). Morbidity, mortality, and sex-specific impacts of COVID-19, Canberra, Australia, 2020. [Online]. Available from: www.chiefscientist.gov.au. [Accessed on 20 May 2023].

[13] Goswami G, Mahapatro M, Ali MA, Rahman R. Do old age and comorbidity via non-communicable diseases matter for COVID-19 mortality? A path analysis. Front Public Heal 2021; 9: 1-16. doi: 10.3389/fpubh.2021.736347.

[14] Nishikimi M, Jafari D, Singh N, Shinozaki K, Sison CP, Shoaib M, et al. Mortality of mechanically ventilated COVID-19 patients in traditional versus expanded intensive care units in New York. Ann Am Thorac Soc 2022; 19(8): 1346-1354. doi: 10.1513/AnnalsATS.202106-705OC.

[15] Mojtaba S, Yousef A, Kolsoom A. COVID-19 mortality trends before and after the national vaccination program in Iran: A joinpoint regression analysis. J Acute Dis 2023; 12(6): 215-218.

[16] Fakili F, Cetinkaya PD, Baydar O, Baris SA, Kokturk N, Kul S, et al. Post-discharge mortality in the first wave of COVID-19 in Turkey. Asian Pac J Trop Med 2022; 15(11): 479-484.

[17] Surendra H, Elyazar IRF, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Heal–West Pac 2021; doi: 10.1016/j.lanwpc.2021.100108.

[18] Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med 2020; 17(9): 1-11. doi: 10.1371/JOURNAL.PMED.1003321.

[19] Lingsma HF, Bottle A, Middleton S, Kievit J, Steyerberg EW, Marang-Van De Mheen PJ, et al. Evaluation of hospital outcomes: The relation between length-of-stay, readmission, and mortality in a large international administrative database. BMC Health Serv Res 2018; 18(1): 1-10. doi: 10.1186/s12913-018-2916-1.

[20] Vekaria B, Overston C, Wisnioski A, Ahmad S, Aparicio CA, Sebastian JC, et al. Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning. BMC Infect Dis 2021; 21(1): 1-15. doi: 10.1186/s12879-021-06371-6.

[21] Oliveira E, Parikh A, Lopez-Ruiz A, Carrito M, Goldberg J, Carras M, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS One 2021; 16(3): 1-14. doi: 10.1371/journal.pone.0249038.

[22] Bae SA, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: A systematic review and meta-analysis. Heart 2021; 107(5): 373-380. doi: 10.1136/heartjnl-2020-317901.

[23] Gülsen A, König IR, Jappe U, Drömann D. Effect of comorbid pulmonary disease on the severity of COVID-19: A systematic review and meta-analysis. Respirology 2021; 26(6): 552-565. doi: 10.1111/resp.14049.

[24] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109(5): 531-538. doi: 10.1007/s00392-020-01626-9.

[25] Ejaz H, Alshrani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health 2020; 13(12): 1833-1839. doi: 10.1016/j.jiph.2020.07.014.